Alternative funding: Disease foundations, govt sources promote available capital
This article was originally published in Scrip
Eager to help firms access capital while government funding is squeezed and venture capitalists are backing away from early-stage technology - and even Big Pharma are cutting research programs - alternative sources of capital are reaching out to the drug development industry.
You may also be interested in...
Green Shoots: Pharma Investments In Early Innovation Support Biotech Growth
Big pharma investments in early innovation are paying off in ways that still are hard to measure in any concrete way, but green shoots are sprouting through the pavement as startups supported by multimillion-dollar initiatives evolve from concept to reality.
Finance Watch: Perlmutter’s Eikon Raises $106m, In-Licenses Pipeline Programs
Private Company Edition: Former Merck R&D head Roger Perlmutter and his new team have accessed drug candidates in oncology and neurodegenerative diseases from three companies, along with new funding. Also, Carmot raised $150m in series E equity and BenchSci brought in $70m.
Eisai/Biogen’s Leqembi Gets Some Medicare Coverage Certainty In CMS Update
CMS said Medicare will cover anti-amyloid antibodies for early Alzheimer’s disease upon traditional approval from the US FDA if prescribed by doctors participating in a patient registry.